Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML, ALL, or MPAL

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia

Interventions

DRUG

MRX-2843

MRX-2843 capsules

Trial Locations (3)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Emory University - WINSHIP Cancer Center, Atlanta

RECRUITING

Emory University, Children's Healthcare of Atlanta, Atlanta

All Listed Sponsors

lead

Meryx, Inc.

INDUSTRY